HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1-(3-astatobenzyl)guanidine

structure given in first source; might prove useful for treating neuroblastoma

Also Known As:

1-(m-astatobenzyl)guanidine; 211At-MABG

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amidines: 14
  - Guanidines: 29
    - 1-(3-astatobenzyl)guanidine: 2

Experts

1.	Higashi, Tatsuya: 2 articles (07/2019 - 01/2018)
2.	Ishioka, Noriko S: 2 articles (07/2019 - 01/2018)
3.	Nagatsu, Kotaro: 2 articles (07/2019 - 01/2018)
4.	Sudo, Hitomi: 2 articles (07/2019 - 01/2018)
5.	Tsuji, Atsushi B: 2 articles (07/2019 - 01/2018)
6.	Yoshinaga, Keiichiro: 2 articles (07/2019 - 01/2018)
7.	Ito, Hiroshi: 1 article (07/2019)
8.	Minegishi, Katsuyuki: 1 article (07/2019)
9.	Sugyo, Aya: 1 article (07/2019)
10.	Ito, Yoichi M: 1 article (01/2018)

Related Diseases

1.	Pheochromocytoma 07/01/2019 - "Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent 211At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice." 01/01/2018 - "Therefore, 211At-MABG might be an effective therapeutic agent for the treatment of malignant pheochromocytoma." 01/01/2018 - "We aimed to evaluate the therapeutic effects of the α-emitter 211At-MABG in a pheochromocytoma model. " 01/01/2018 - "211At-MABG exhibited a strong tumor volume-reducing effect in a mouse model of pheochromocytoma without weight reduction. "
2.	Weight Loss (Weight Reduction) 01/01/2018 - "In addition, the mice treated with 0.28, 0.56 and 1.11 MBq of 211At-MABG showed only a temporary weight reduction, with recovery in weight by day 10. " 01/01/2018 - "211At-MABG exhibited a strong tumor volume-reducing effect in a mouse model of pheochromocytoma without weight reduction. "
3.	Neoplasms (Cancer) 01/01/2018 - "Tumor volumes were evaluated for 8 weeks after 211At-MABG administration. " 01/01/2018 - "We evaluated tumor volume-reducing effects of 211At-MABG using rat pheochromocytoma cell line PC12 tumor-bearing mice. " 01/01/2018 - "PC12 tumor-bearing mice received intravenous injections of 211At-MABG (0.28, 0.56, 1.11, 1.85, 3.70 and 5.55 MBq; five mice per group). " 01/01/2018 - "211At-MABG exhibited a strong tumor volume-reducing effect in a mouse model of pheochromocytoma without weight reduction. "
4.	Body Weight (Weight, Body) 07/01/2019 - "The administration of 1.1, 2.2, and 3.3 MBq of 211At-MABG induced transient body weight loss, and 4.4 MBq of 211At-MABG induced unrecoverable body weight loss; thus, the MTD was 3.3 MBq for ICR mice. " 07/01/2019 - "We determined the maximum tolerated doses (MTD) of 211At-MABG on the basis of body weight loss and assessed the acute radiation-related toxicity induced by MTD administration on the basis of organ weights, histologic features, hematologic indices, and biochemical indices. "

Related Drugs and Biologics

1.	Therapeutic Uses

Related Therapies and Procedures

1.	Intravenous Injections